Endocrinology and Metabolism10.3803/enm.2021.102202136122-29Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor AgonistsHun Jee Choe, Young Min Cho,,
European Journal of Pharmacology10.1016/j.ejphar.2004.08.02320045011-3225-234Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonistsQing Dallas-Yang, Xiaolan Shen, Mathias Strowski, Edward Brady, Richard Saperstein, Raymond E. Gibson, Deborah Szalkowski, Sajjad A. Qureshi, Mari Rios Candelore, Judith E. Fenyk-Melody, Emma R. Parmee, Bei B. Zhang, Guoqiang Jiang,
Appetite10.1016/j.appet.2011.05.226201157S29Glucagon-like peptide-1 receptor agonists suppress water intakeN.J. Mckay, S.E. Kanoski, M.R. Hayes, D. Daniels,
BMJ10.1136/bmj.i55192016i5519Glucagon-like peptide-1 receptor agonists and risk of breast cancerShari D Bolen, Nisa M Maruthur,
Journal of the Endocrine Society10.1210/jendso/bvaa201202153Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM,
Pancreatology10.1016/j.pan.2019.05.115201919S45-S46Risk of acute pancreatitis after glucagon-like peptide-1 receptor agonistsAdriana Gherbon,
Progress in Medicinal Chemistry10.1016/b978-0-444-62652-3.00002-8201345-96Medicinal Chemistry of Glucagon-Like Peptide Receptor AgonistsLyn H. Jones, David A. Price,
Cardiovascular Research10.1093/cvr/cvy124201811410e70-e71Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCELSigne Sørensen Torekov
Handbook of Incretin-based Therapies in Type 2 Diabetes10.1007/978-3-319-08982-9_3201631-43Glucagon-like peptide-1 receptor agonistsBaptist Gallwitz
Journal of Diabetes Investigation10.1111/j.2040-1124.2012.00241.x201236490-491Glucagon-like peptide-1 receptor agonists and their effects on weight reductionShyi-Jang Shin,